

# FINAL PROGRAM

APRIL 11 & 12, 2024 - INSTITUT CURIE  
AMPHITHEATER CONSTANT BURG, FRANCE



## THE PATHOLOGY OF MELANOMA: AN INTERNATIONAL COURSE

### DIRECTED BY:



Director of Course  
Pr Raymond Barnhill,  
Paris, France



Pr Boris Bastian,  
San Francisco, USA



Pr Klaus Busam,  
New York, USA



Pr David Elder  
Philadelphia, USA



Pr Richard Scolyer  
Sydney, Australia

### OBJECTIVE

Following the success of our Courses in 2017, 2018, 2020, and 2022 the objective of the Fifth International Melanoma Course in 2024 will continue to stress due diligence and practical diagnosis of melanocytic lesions. We will emphasize the theme of "Acknowledging uncertainty and avoiding over diagnosis of melanoma", as well as updates of all cutting-edge knowledge on difficult melanocytes lesions relevant to practicing pathologists and clinicians.

This 2024 venue will again include expertise from the SiRIC (Integrated Cancer Research Site at Institut Curie), the WHO 5th Edition Classification of Melanocytic Tumours, the revised MPATH-Dx Classification schema (2023), the MPATH Group, and the International Melanoma Pathology Study Group.

### THE REVISED MPATH-DX CLASSIFICATION

- Online access in advance and review of digitized images from extensively-characterized cases constituting the MPath study set. This unique study set has been reviewed by the MPath Pathology Panel (Prs. Barnhill, Elder, and Piepkorn), and a large diverse group of pathologists.
- The Course will be practical and based on the extensive experience of the international faculty participating in the Course. The Course will consist of didactic lectures and interactive sessions during the two-day program.

### THE COURSE PROGRAMME AND CONTENT

- The Course will consist of didactic lectures and interactive sessions during the two-day program.
- An approach of practical diagnosis is based on the extensive experience of the international faculty in the Course.
- The latest advances in ancillary diagnostic techniques including immunohistochemistry and molecular genetics will be emphasized.
- Particular attention will be given to predictive biomarkers for targeted, immune and checkpoint inhibitors therapies.





# FINAL PROGRAM

## THURSDAY, APRIL 11<sup>TH</sup>

- 08.15 Introduction.** **Raymond Barnhill**
- 08.20** Criteria for melanocytic lesions : an introduction. **Raymond Barnhill**
- 08.50** Immunohistochemistry for pathologists. **Klaus Busam**
- 09.20** Molecular diagnostics for pathologists. **Boris Bastian**
- 10.00 Coffee Break**
- 10.30** MPath classification. **Raymond Barnhill**
- 10.50** AJCC 8<sup>th</sup> edition guidelines. **David Elder**
- 11.10** Sentinel lymph nodes and prognostic factors in melanoma, **Lyn Duncan**
- 11.30** Treatment recommendations for melanocytic lesions. **David Elder**

### 12.00 Lunch

- 01.00<sup>PM</sup>** Classification of melanoma for pathologists. **Boris Bastian**
- 01.30<sup>PM</sup>** Lentigo maligna melanoma. **Klaus Busam**
- 01.50<sup>PM</sup>** Ocular conjunctival and uveal melanocytic lesions: Clinical aspects. **Denis Malaise**
- 02.10<sup>PM</sup>** Conjunctival melanocytic lesions: Pathological aspects. **Ian Cree**
- 02.25<sup>PM</sup>** Uveal melanoma: Pathological aspects. **Raymond Barnhill**
- 02.40<sup>PM</sup>** Angiotropic extravascular migratory metastasis. **Claire Lugassy**

### 03.00<sup>PM</sup> Coffee Break

- 03.30<sup>PM</sup> Case presentations**  
(10 cases, 10 min/case with discussion)

### 05.30<sup>PM</sup> End of the day

### 05.45<sup>PM</sup> Welcome cocktail

## FRIDAY, APRIL 12<sup>TH</sup>

- 08.10** Acquired melanocytic nevi. **David Elder**
- 08.40** Spitz nevus, atypical Spitz tumor, Spitz melanoma. **Raymond Barnhill**
- 09.10** Blue nevus and melanoma arising in blue nevus. **Arnaud de la Fouchardière**
- 09.40** Site-specific nevi (including scalp, breast and milk-line, flexural, perianal). **David Elder**

### 10.00 Coffee Break

- 10.30** Combined melanocytic nevi: BAP1, deep penetrating, pigmented epithelioid melanocytoma, etc **Arnaud de la Fouchardière**
- 10.50** Pediatric melanocytic lesions. **Raymond Barnhill**
- 11.10** Acral melanocytic nevi and melanoma. **Richard Scolyer**
- 11.40** Melanoma of unknown primary: differential diagnosis, **Lyn Duncan**

### 12.10 Lunch

- 01.10<sup>PM</sup>** Nevoid melanoma. **Klaus Busam**
- 01.30<sup>PM</sup>** Desmoplastic nevi and desmoplastic melanoma. **Klaus Busam**
- 01.50<sup>PM</sup>** Oral and genital melanocytic lesions. **Ian Cree**
- 02.10<sup>PM</sup>** Sinonasal melanoma, **Lyn Duncan**
- 02.30<sup>PM</sup>** Gene expression profiling in melanocytic lesions: an update, **Matthew Goldberg**

### 03.00<sup>PM</sup> Coffee Break

- 03.30<sup>PM</sup> Case presentations continued**

### 05.30<sup>PM</sup> End of the Course



## LIST OF SPEAKERS

**Pr Raymond Barnhill,**

Institut Curie and University of Paris Cité  
Paris, France

**Pr Boris Bastian,**

University of California, San Francisco, USA

**Pr Klaus Busam,**

Memorial Sloan Kettering Cancer Center,  
New York, USA

**Pr Ian Cree,**

University College London, United Kingdom

**Pr Lyn Duncan**

Massachusetts General Hospital and Harvard  
Medical School, Boston, USA

**Pr David Elder,**

University of Pennsylvania, Philadelphia USA

**Dr Arnaud de la Fouchardière,**

Centre Léon Bérard, Lyon, France

**Dr Matthew Goldberg,**

Senior Vice President, Castle Biosciences, Inc.

**Dr Claire Lugassy,**

Institut Curie, Paris, France

**Dr Denis Malaise,** Institut Curie,

Paris, France

**Pr Richard Scolyer,**

Melanoma Institute of Australia  
and the University of Sydney, Australia

# Changing the way patients are diagnosed and managed

We provide **more than just a test result** - our gene expression profile tests provide accurate, objective, and personalized answers that can help guide informed decisions and improve care for patients with melanoma.

## Decision Dx ► Melanoma

Provides comprehensive, personalized, genomic tumor information to guide management for patients with cutaneous melanoma

## MyPath ► Melanoma

Aids in the diagnosis and management decisions for patients with challenging or ambiguous melanocytic lesions



Learn more at  
[castlebiosciences.com](https://castlebiosciences.com)

